Log in to save to my catalogue

Remdesivir for the Treatment of Covid-19 — Final Report

Remdesivir for the Treatment of Covid-19 — Final Report

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7262788

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In this randomized, double-blind trial in 1062 adults hospitalized with Covid-19, remdesivir was superior to placebo in shortening the time to recovery (10 days, vs. 15 days with placebo). The estimates of mortality by day 29 were 11.4% with remdesivir and 15.2% with placebo. The benefit of remdesivir was most apparent in patients who were receivin...

Alternative Titles

Full title

Remdesivir for the Treatment of Covid-19 — Final Report

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7262788

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7262788

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2007764

How to access this item